Nordic Nanovector receives Promising Innovative Medicine Designation

This acknowledges the potential of Betalutin® to offer therapeutic benefits to patients with follicular lymphoma, says CMO Lisa Rojkjaer in a press release.
October 25, 2018/by Elisabeth K. Andersen

Om Vaccibody i NRK EKKO

NRK EKKO med innslag om vår porteføljebedrift Vaccibody.
October 24, 2018/by Elisabeth K. Andersen

Targovax: Reports full data set on clinical trial of cancer vaccine TG01

Our portfolio company Targovax reports encouraging disease-free…
October 16, 2018/by Elisabeth K. Andersen

Vaccibody: First 10 patients enrolled and vaccination started

Our portfolio company Vaccibody has released an update on the…
October 10, 2018/by Elisabeth K. Andersen

Targovax: Encouraging interim results of ONCOS-102

Our portfolio company Targovax has released interim results…
September 30, 2018/by Elisabeth K. Andersen

Vaccibody in collaboration with prestige company Nektar Therapeutics

Our portolio company Vaccibody AS just entered a clinical collaboration…
September 24, 2018/by Elisabeth K. Andersen

New CEO in Photocure

Our portfolio company Photocure ASA has appointed Daniel Schneider…
September 24, 2018/by Elisabeth K. Andersen

Vi feirer 50 episoder med podkast

Vi har nå kommet til episode 50 i vår podkast RADIUM. Det feires…
June 14, 2018/by Elisabeth K. Andersen

Update on PARADIGME from Nordic Nanovector

Our portfolio company Nordic Nanovector provided an update on…
April 11, 2018/by Elisabeth K. Andersen

Vaccibody with informed consent from first patient

The news got the front page of VG.
April 11, 2018/by Elisabeth K. Andersen

PCI Biotech: “A transformative year”

Our portfolio company PCI Biotech published their full year report for 2017 today. 
March 20, 2018/by Elisabeth K. Andersen

Podkasten Radium går live – og vi vil se deg!

Podkasten Radium forflytter seg ut av studioet i Oslo Cancer…
March 7, 2018/by Elisabeth K. Andersen